Benazepril clinical studies: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Amr Marawan (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Benazepril}} | {{Benazepril}} | ||
{{CMG}} | {{CMG}} ; {{AE}} {{AM}} | ||
==Clinical Studies== | ==Clinical Studies== | ||
| Line 14: | Line 14: | ||
The antihypertensive effects of Lotensin were not appreciably different in patients receiving high- or low-sodium diets. | The antihypertensive effects of Lotensin were not appreciably different in patients receiving high- or low-sodium diets. | ||
In normal human volunteers, single doses of benazepril caused an increase in renal blood flow but had no effect on glomerular filtration rate. | In normal human volunteers, single doses of benazepril caused an increase in [[renal blood flow]] but had no effect on [[glomerular filtration rate]]. | ||
Use of Lotensin in combination with thiazide diuretics gives a blood-pressure-lowering effect greater than that seen with either agent alone. By blocking the renin-angiotensin-aldosterone axis, administration of Lotensin tends to reduce the potassium loss associated with the diuretic. | Use of Lotensin in combination with [[thiazide diuretics]] gives a blood-pressure-lowering effect greater than that seen with either agent alone. By blocking the renin-angiotensin-aldosterone axis, administration of Lotensin tends to reduce the [[potassium]] loss associated with the diuretic. | ||
======Pediatric====== | ======Pediatric====== | ||
In a clinical study of 107 pediatric patients, 7 to 16 years of age, with either systolic or diastolic pressure above the 95th percentile, patients were given 0.1 or 0.2 mg/kg then titrated up to 0.3 or 0.6 mg/kg with a maximum dose of 40 mg once daily. After four weeks of treatment, the 85 patients whose blood pressure was reduced on therapy were then randomized to either placebo or benazepril and were followed up for an additional two weeks. At the end of two weeks, blood pressure (both systolic and diastolic) in children withdrawn to placebo rose by 4 to 6 mmHg more than in children on benazepril. No dose-response was observed for the three doses.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LOTENSIN (BENAZEPRIL HYDROCHLORIDE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d954024-a191-46e3-ba71-2a7d5b0c65d5#nlm34067-9 | publisher = | date = | accessdate = }}</ref> | In a clinical study of 107 pediatric patients, 7 to 16 years of age, with either [[systolic]] or [[diastolic pressure]] above the 95th percentile, patients were given 0.1 or 0.2 mg/kg then titrated up to 0.3 or 0.6 mg/kg with a maximum dose of 40 mg once daily. After four weeks of treatment, the 85 patients whose blood pressure was reduced on therapy were then randomized to either placebo or benazepril and were followed up for an additional two weeks. At the end of two weeks, blood pressure (both systolic and diastolic) in children withdrawn to placebo rose by 4 to 6 mmHg more than in children on benazepril. No dose-response was observed for the three doses.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LOTENSIN (BENAZEPRIL HYDROCHLORIDE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d954024-a191-46e3-ba71-2a7d5b0c65d5#nlm34067-9 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 20:35, 11 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [2]
Clinical Studies
Hypertension
Adult
In single-dose studies, Lotensin lowered blood pressure within 1 hour, with peak reductions achieved 2-4 hours after dosing. The antihypertensive effect of a single dose persisted for 24 hours. In multiple-dose studies, once-daily doses of 20-80 mg decreased seated pressure (systolic/diastolic) 24 hours after dosing by about 6-12/4-7 mmHg. The trough values represent reductions of about 50% of that seen at peak.
Four dose-response studies using once-daily dosing were conducted in 470 mild-to-moderate hypertensive patients not using diuretics. The minimal effective once-daily dose of Lotensin was 10 mg; but further falls in blood pressure, especially at morning trough, were seen with higher doses in the studied dosing range (10-80 mg). In studies comparing the same daily dose of Lotensin given as a single morning dose or as a twice-daily dose, blood pressure reductions at the time of morning trough blood levels were greater with the divided regimen.
The antihypertensive effects of Lotensin were not appreciably different in patients receiving high- or low-sodium diets. In normal human volunteers, single doses of benazepril caused an increase in renal blood flow but had no effect on glomerular filtration rate. Use of Lotensin in combination with thiazide diuretics gives a blood-pressure-lowering effect greater than that seen with either agent alone. By blocking the renin-angiotensin-aldosterone axis, administration of Lotensin tends to reduce the potassium loss associated with the diuretic.
Pediatric
In a clinical study of 107 pediatric patients, 7 to 16 years of age, with either systolic or diastolic pressure above the 95th percentile, patients were given 0.1 or 0.2 mg/kg then titrated up to 0.3 or 0.6 mg/kg with a maximum dose of 40 mg once daily. After four weeks of treatment, the 85 patients whose blood pressure was reduced on therapy were then randomized to either placebo or benazepril and were followed up for an additional two weeks. At the end of two weeks, blood pressure (both systolic and diastolic) in children withdrawn to placebo rose by 4 to 6 mmHg more than in children on benazepril. No dose-response was observed for the three doses.[1]
References
Adapted from the FDA Package Insert.